Literature DB >> 19720533

Sporadic inclusion body myositis: HLA-DRB1 allele interactions influence disease risk and clinical phenotype.

Frank L Mastaglia1, Merrilee Needham, Adrian Scott, Ian James, Paul Zilko, Timothy Day, Lynette Kiers, Alastair Corbett, Campbell S Witt, Richard Allcock, Nigel Laing, Michael Garlepp, Frank T Christiansen.   

Abstract

Susceptibility to sIBM is strongly associated with the HLA-DRB1*03 allele and the 8.1 MHC ancestral haplotype (HLA-A1, B8, DRB1*03) but little is known about the effects of allelic interactions at the DRB1 locus or disease-modifying effects of HLA alleles. HLA-A, B and DRB1 genotyping was performed in 80 Australian sIBM cases and the frequencies of different alleles and allele combinations were compared with those in a group of 190 healthy controls. Genotype-phenotype correlations were also investigated. Amongst carriers of the HLA-DRB1*03 allele, DRB1*03/*01 heterozygotes were over-represented in the sIBM group (p<0.003) while. DRB1*03/*04 heterozygotes were under-represented (p<0.008). The mean age-at-onset (AAO) was 6.5 years earlier in DRB1*03/*01 heterozygotes who also had more severe quadriceps muscle weakness than the rest of the cohort. The findings indicate that interactions between the HLA-DRB1*03 allele and other alleles at the DRB1 locus can influence disease susceptibility and the clinical phenotype in sIBM.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19720533     DOI: 10.1016/j.nmd.2009.07.015

Source DB:  PubMed          Journal:  Neuromuscul Disord        ISSN: 0960-8966            Impact factor:   4.296


  15 in total

Review 1.  Sporadic inclusion body myositis: variability in prevalence and phenotype and influence of the MHC.

Authors:  F L Mastaglia
Journal:  Acta Myol       Date:  2009-10

2.  Increased frequency of DRB1*11:01 in anti-hydroxymethylglutaryl-coenzyme A reductase-associated autoimmune myopathy.

Authors:  Andrew L Mammen; Daniel Gaudet; Diane Brisson; Lisa Christopher-Stine; Thomas E Lloyd; Mary S Leffell; Andrea A Zachary
Journal:  Arthritis Care Res (Hoboken)       Date:  2012-08       Impact factor: 4.794

Review 3.  Inclusion Body Myositis: Update on Pathogenesis and Treatment.

Authors:  Elie Naddaf; Richard J Barohn; Mazen M Dimachkie
Journal:  Neurotherapeutics       Date:  2018-10       Impact factor: 7.620

4.  Proteomics of rimmed vacuoles define new risk allele in inclusion body myositis.

Authors:  Anne-Katrin Güttsches; Stefen Brady; Kathryn Krause; Alexandra Maerkens; Julian Uszkoreit; Martin Eisenacher; Anja Schreiner; Sara Galozzi; Janine Mertens-Rill; Martin Tegenthoff; Janice L Holton; Matthew B Harms; Thomas E Lloyd; Matthias Vorgerd; Conrad C Weihl; Katrin Marcus; Rudolf A Kley
Journal:  Ann Neurol       Date:  2017-01-27       Impact factor: 10.422

Review 5.  New Developments in the Genetics of Inclusion Body Myositis.

Authors:  Kyla A Britson; Stephanie Y Yang; Thomas E Lloyd
Journal:  Curr Rheumatol Rep       Date:  2018-04-02       Impact factor: 4.592

Review 6.  Myositis registries and biorepositories: powerful tools to advance clinical, epidemiologic and pathogenic research.

Authors:  Lisa G Rider; Katalin Dankó; Frederick W Miller
Journal:  Curr Opin Rheumatol       Date:  2014-11       Impact factor: 5.006

Review 7.  Recent advances in the immunogenetics of idiopathic inflammatory myopathy.

Authors:  Hector Chinoy; Janine A Lamb; William E R Ollier; Robert G Cooper
Journal:  Arthritis Res Ther       Date:  2011-05-26       Impact factor: 5.156

8.  Genome-wide association study identifies HLA 8.1 ancestral haplotype alleles as major genetic risk factors for myositis phenotypes.

Authors:  F W Miller; W Chen; T P O'Hanlon; R G Cooper; J Vencovsky; L G Rider; K Danko; L R Wedderburn; I E Lundberg; L M Pachman; A M Reed; S R Ytterberg; L Padyukov; A Selva-O'Callaghan; T R Radstake; D A Isenberg; H Chinoy; W E R Ollier; P Scheet; B Peng; A Lee; J Byun; J A Lamb; P K Gregersen; C I Amos
Journal:  Genes Immun       Date:  2015-08-20       Impact factor: 2.676

Review 9.  Emerging therapeutic options for sporadic inclusion body myositis.

Authors:  Lindsay N Alfano; Linda P Lowes
Journal:  Ther Clin Risk Manag       Date:  2015-09-25       Impact factor: 2.423

Review 10.  Ongoing developments in sporadic inclusion body myositis.

Authors:  Pedro M Machado; Mhoriam Ahmed; Stefen Brady; Qiang Gang; Estelle Healy; Jasper M Morrow; Amanda C Wallace; Liz Dewar; Gita Ramdharry; Matthew Parton; Janice L Holton; Henry Houlden; Linda Greensmith; Michael G Hanna
Journal:  Curr Rheumatol Rep       Date:  2014-12       Impact factor: 4.592

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.